UI Hospitals and Clinics
A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patient with CD30-positive mature T-cell lymphomas: the ARROVEN study
Participants in this study have CD-30 positive Mature T-cell Lymphomas (MTCL) that have never been treated. The standard of care for patients with newly diagnosed MTCL is treatment with a combination of drugs called CHOP [cyclophosphamide, hydroxydoxorubicin (also called doxorubicin), vincristine (Oncovin-R), and prednisone]. This study is being done to compare CHOP to a combination of treatment that replaces vincristine with brentuximab vedotin. This combination is called A+CHP [brentuximab vedotin (ADCETRIS-R) plus cyclophosphamide, hydroxydorubicin, and prednisone]. About 300 people will take part in this research study at approximately 90 sites in North America, Europe, and Asia.
Susan Gillen, 319-467-5827
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.